| LM-group (n=171) | HM-group (n=639) | P | |
|---|---|---|---|
| Age, years | 58 (47–69) | 61 (51–69) | 0.13 |
| Gender, % female | 70 | 60 | 0.03 |
| Disease duration, months | 6 (3–11) | 6 (3–11) | 0.65 |
| Tender joint count | 7 (3–13) | 5 (2–11) | 0.05 |
| Swollen joint count | 5 (2–9) | 5 (2–10) | 0.62 |
| Physician VAS, mm | 47 (27–67) | 33 (18–50) | 0.0001 |
| Patient VAS, mm | 50 (26–70) | 35 (20–55) | 0.0001 |
| DAS28 score at baseline | 4.2 (3.4–5.2) | 4.1 (3.2–5.1) | 0.24 |
| DAS28 score at 6 months | 3.5 (2.7, 4.1) | 3.0 (2.2, 4.1) | 0.004 |
| HAQ score | 1.3 (0.6–1.8) | 0.9 (0.4–1.5) | 0.001 |
| Other nbDMARD use, n (%) | 30 (17) | 61 (10) | 0.003 |
| EULAR response at 6 months, n (%) | 0.09 | ||
| Non-responders | 50 (45) | 184 (42) | |
| Moderate responders | 36 (32) | 108 (25) | |
| Good responders | 26 (23) | 145 (33) | |
| Fully adjusted RRR (95% CI)* | |||
| Non-responders | – | ref | |
| Moderate responders | – | 1.01 (0.56, 1.82) | 0.97 |
| Good responders | – | 2.65 (1.37, 5.14) | 0.004 |
Scores are median [IQR].